Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies

Pratap Neelakantan, Gareth Gerrard, Claire Lucas, Dragana Milojkovic, Philippa May, Lihui Wang, Christos Paliompeis, Marco Bua, Alistair Reid, Katayoun Rezvani, Stephen O'Brien, Richard Clark, John Goldman, David Marin

Blood (2013) 121 (14): 2739–2742.

https://doi.org/10.1182/blood-2012-11-466037

Published: 2013

Includes: Supplemental data

Journal Articles

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia

Athina Giannoudis, Lihui Wang, Andrea L. Jorgensen, George Xinarianos, Andrea Davies, Sudeep Pushpakom, Triantafilos Liloglou, Jieying-Eunice Zhang, Gemma Austin, Tessa L. Holyoake, Letizia Foroni, Panagiotis D. Kottaridis, Martin C. Müller, Munir Pirmohamed, Richard E. Clark

Blood (2013) 121 (4): 628–637.

https://doi.org/10.1182/blood-2012-01-405035

Published: 2013

Includes: Supplemental data

Journal Articles

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib

Dragana Milojkovic, MD, Amr R Ibrahim, Letizia Foroni, MD PhD, Claire Lucas, Gareth Gerrard, PhD, Lihui Wang, Richard M Szydlo, Richard E Clark, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Marco Bua, MD, Jiri Pavlu, Christos Paliompeis, Alistair Reid, PhD, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, David Marin

Blood (2011) 118 (21): 1680.

https://doi.org/10.1182/blood.V118.21.1680.1680

Published: 2011

Journal Articles

EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors

Mustafa Daghistani, David Marin, Jamshid Sorouri Khorashad, Lihui Wang, Philippa C. May, Christos Paliompeis, Dragana Milojkovic, Valeria A. De Melo, Gareth Gerrard, John M. Goldman, Jane F. Apperley, Richard E. Clark, Letizia Foroni, Alistair G. Reid

Blood (2010) 116 (26): 6014–6017.

https://doi.org/10.1182/blood-2010-01-264234

Published: 2010

Includes: Supplemental data

Journal Articles

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA

Blood (2010) 116 (22): e111–e117.

https://doi.org/10.1182/blood-2010-06-291641

Published: 2010

Includes: Supplemental data

Journal Articles

Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds

Martin C. Müller, MD, Umang Munjal, PhD, Philipp Erben, MD, Thomas Lion, MD, PhD, Gerlinde Mitterbauer-Hohendanner, MD, Hakim El Housni, MD, Nancy Boeckx, Renata Zadro, MD, PhD, Jiri Mayer, MD, PhD, Peter Rohon, MD, Jana Rulcova, PhD, Lykke Grubach, Kadri Raudsepp, MD, Veli Kairisto, MD, PhD, Francois-Xavier Mahon, MD, PhD, Claude Preudhomme, MD, Sandrine Hayette, MD, Jean Gabert, MD, Jean-Michel Cayuela, MD, PhD, Christian Thiede, Lars Galonska, MD, Heike Pfeifer, MD, Carsten Hirt, MD, Philippe Schafhausen, MD, Nils von Neuhoff, PhD, Martin Roskos, MD, Christiane Pott, MD, Thoralf Lange, MD, Georg Hess, MD, Susanne Schnittger, PhD, Annika Dufour, MD, Steffen Koschmieder, MD, Frank Stegelmann, MD, Katerina Zoi, MD, PhD, Kostas Stamatopoulos, Hajnalka Andrikovics, MD, PhD, Tali Tohami, MD, PhD, Giovanni Martinelli, MD, Barbara Izzo, PhD, Enrico Gottardi, MD, Mindaugas Stoskus, Dag Andre Nymoen, MD, Tomasz Sacha, MD, Joana Diamond, MD, PhD, Rodica Talmaci, PhD, Andrey Misyurin, MD, Michael V. Dubina, MD, Tadej Pajic, MD, PhD, Josep F. Nomdedeu, MD, Dolors Colomer, MD, PhD, Gisela Barbany-Bustinza, MD, Hans Ehrencrona, MD, Elisabeth Oppliger Leibundgut, PhD, Jeroen Janssen, MD, Vincent H. J. van der elden, MD, Peter J.M. Valk, MD, PhD, Ugur Ozbek, MD, PhD, Lihui Wang, Gareth Gerrard, PhD, Helen E White, PhD, Thomas Schenk, MD, Thomas Ernst, MD, Rüdiger Hehlmann, MD, Giuseppe Saglio, MD, PhD, Andreas Hochhaus, MD, Nicholas C. P. Cross, PhD

Blood (2010) 116 (21): 893.

https://doi.org/10.1182/blood.V116.21.893.893

Published: 2010

Journal Articles

Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype.

Xiaoyan Jiang, MD, PhD, Hannah Grant, PhD, Justin Stebbing, MD, PhD, Letizia Foroni, MD, Charles Craddock, BM, MRCP, MRCPah, MD, Mike Griffiths, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Stephen O'Brien, MD, PhD, Jamshid S. Khorashad, MD, PhD, Gareth Gerrard, MD, PhD, Lihui Wang, MD, PhD, Julie Irving, PhD, Meng Wang, PhD, Loraine Karran, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Donna L. Forrest, MD, Karen Page, MA, PhD, Connie J. Eaves, PhD, Adrian Woolfson, PhD

Blood (2010) 116 (21): 3397.

https://doi.org/10.1182/blood.V116.21.3397.3397

Published: 2010

Journal Articles

Clinical and Functional Evidence That Drug Transporter Expression Dictates the Response to Imatinib in Chronic Myeloid Leukaemia.

Lihui Wang, MD, Athina Giannoudis, PhD, Steven Lane, PhD, Paula R. Williamson, PhD, Munir Pirmohamed, PhD, Richard E. Clark, MD

Blood (2006) 108 (11): 2145.

https://doi.org/10.1182/blood.V108.11.2145.2145

Published: 2006

Journal Articles

Active transport of imatinib into and out of cells: implications for drug resistance

Julia Thomas, Lihui Wang, Richard E. Clark, Munir Pirmohamed

Blood (2004) 104 (12): 3739–3745.

https://doi.org/10.1182/blood-2003-12-4276

Published: 2004

Journal Articles

BCR-ABL–specific T cells can be detected in healthy donors and in chronic myeloid leukemia patients following allogeneic stem cell transplantation

Nauman M. Butt, Lihui Wang, Hazem M. Abu-Eisha, Steve E. Christmas, Richard E. Clark

Blood (2004) 103 (8): 3245.

https://doi.org/10.1182/blood-2003-11-4086

Published: 2004

Journal Articles

Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein

Richard E. Clark, I. Anthony Dodi, Seran C. Hill, Jennie R. Lill, Geraldine Aubert, Andrew R. Macintyre, Jose Rojas, Audrey Bourdon, Philip L. R. Bonner, Lihui Wang, Stephen E. Christmas, Paul J. Travers, Colin S. Creaser, Robert C. Rees, J. Alejandro Madrigal

Blood (2001) 98 (10): 2887–2893.

https://doi.org/10.1182/blood.V98.10.2887

Published: 2001

NARROW

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib

EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA

Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds

Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype.

Clinical and Functional Evidence That Drug Transporter Expression Dictates the Response to Imatinib in Chronic Myeloid Leukaemia.

Active transport of imatinib into and out of cells: implications for drug resistance

BCR-ABL–specific T cells can be detected in healthy donors and in chronic myeloid leukemia patients following allogeneic stem cell transplantation

Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only